Prostate Cancer Information: Article Series

Prostate Cancer Information

Advanced Prostate Cancer

Comparison of Percent-Free PSA, PSA Density, and Age-Specific PSA Cutoffs for Prostate Cancer Detection and Staging
W.J. Catalona; P.C. Southwick; K.M. Slawin; A.W. Partin; M.K. Brawer; R.C. Flanigan, et al.
Urology, August 2000 This study concludes that the percent-free PSA test was either equal to or better than two other methods of detecting prostate cancer. Researchers examined three methods: age-specific PSA reference ranges, PSA density (PSAD), and percent-free PSA. Researchers found that the free PSA assay was significantly better than age-specific PSA reference ranges. Percent-free PSA and PSA density provided equally accurate results. This paper states the free PSA assay may be used in place of PSAD to determine whether a biopsy was necessary and to help make treatment decisions.

(click for a larger version)

The Prostate Cancer Education Council's Article Series consists of articles written by a select panel of distinguished urologists from across the nation. Each article addresses a topic related to advancements in prostate cancer treatment, research, and prevention. Informative sidebars accompany each segment, along with highlighted technical vocabulary hyperlinked to a prostate cancer glossary, creating an easily digestible format for consumers.

The current article series includes:

Value of PSA and Free PSA Tests Validated in New Prostate Cancer Guidelines
Features William J. Catalona, M.D., professor at Washington University in St. Louis

PSA Test a Cause for Concern? Not So Fast
Features William J. Catalona, M.D., professor at Washington University in St. Louis

PSA: What's the Prognosis?
Features William J. Catalona, M.D., professor at Washington University in St. Louis

Evaluating PSA Levels in Men on Oral Medication to Treat Prostate Disease
Features William J. Catalona, M.D., professor at Washington University in St. Louis

5 in 5: Take Five Minutes for Five Questions about Prostate Cancer
Mark A. Moyad, MD, MPH ; Phil F Jenkins, Director of Complementary/Preventive Medicine

Personal Perspectives on Current Prostate Cancer Topics
Mark A. Moyad, MPH

Selenium and Vitamin E Supplements for Prostate Cancer: Evidence or Embellishment?
Mark A. Moyad, MPH

The Role of Urodynamics in Assessing Symptomatic Benign Prostatic Hyperplasia
Ian K. Walsh, MD, FRCS; Anthony R. Stone, MD, FRCS

Immediate versus Delayed Therapy for Prostate Cancer: Earlier is Better
E. David Crawford, M.D.

Use of the LigaSure™ Vessel Sealing System in Urologic Cancer Surgery
E. David Crawford, MD; Jenifer S. Kennedy, PhD; Vonne Sieve

Article Archives:

Alternative Therapies for Reducing Hot Flashes in Patients on Luteinizing Hormone-Releasing Hormone Agonist Treatment/Orchiectomy for Prostate Cancer: A Review and the Need for More Research
Mark A. Moyad, MPH

Senate Hearing on Prostate Cancer: The Silent Killer
E. David Crawford, MD

Long-Term Follow-Up of Four Patients With Advanced Prostate Cancer Treated With Nilutamide After Failure of Other Antiandrogens
Bülent Akduman, MD; E. David Crawford, MD; Ali M. Ziada, MD

Prostate Specific Antigen: Recurrence After Therapy
Dr. E. David Crawford
Professor of Surgery and Radiation Oncology, and head of the Section of Urologic Oncology at the University of Colorado Health Sciences Center, Denver, CO.

When Patients Ask About Surgery Versus Radiation for Early Stage Prostate Cancer
Col. Judd W. Moul
Associate Professor of Surgery at the Uniformed Services University of the Health Sciences, Bethesda, MD, and attending Urologic Oncologist at the Walter Reed Army Medical Center, Washington, DC.

Prostate Brachytherapy: A Patient's Perspective
Dr. Nelson N. Stone
Professor of Urology and Radiation Oncology at the Mount Sinai Medical Center, New York, New York.

Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer
Col. David G. McLeod, M.D.
Chief of Urologic Oncology, Walter Reed Army Medical Center, Washington, D.C.
Professor of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Md.
Director of the Urology residence program at Walter Reed
Clinical Professor in the Department of Surgery (Urology), Georgetown University Medical Center.

In-111 Capromab Pendetide (ProstaScint7) in the Evaluation of Prostate-Specific Antigen-Only Progression of Prostate Cancer
Col. Judd W. Moul
Associate Professor of Surgery at the Uniformed Services University of the Health Sciences, Bethesda, MD, and attending Urologic Oncologist at the Walter Reed Army Medical Center, Washington, DC.

Comparative Study of the Clinical Efficacy of Two Dosing Regimens of Flutamide
Dr. J. Brantley Thrasher
William L. Valk Distinguished Professor and Chairman of the Section of Urology at the University of Kansas Medical Center, Kansas City, Kansas.

Founded in 1988, the PCEC is a consortium of physicians, health educators, scientists, and patient advocates dedicated to increasing prostate cancer awareness and knowledge. Find out more about the PCEC and Prostate Cancer Awareness Week here.